MOUNTAIN VIEW, Calif., Oct. 20, 2015 /PRNewswire/ -- Applications following sample preparation are driving product development in the U.S. nucleic acid purification and isolation (NAPI) market. Prominent downstream applications behind this trend include next-generation sequencing, molecular diagnostics testing, forensics, epigenetics, research on free-circulating nucleic acids, use of formalin-fixed paraffin-embedded samples, exosome research, and pharmacogenomics. The uptake of these popular applications requiring NAPI on the front-end of the workflow is translating into growth for the market.
New analysis from Frost & Sullivan, US Nucleic Acid Purification and Isolation Markets (http://www.frost.com/sublib/display-report.do?id=NF16-01-00-00-00&src=PR), finds the market is estimated to reach $811 million in 2021 and is growing at a compound annual growth rate of 5.7 percent.
For complimentary access to more information on this research, please visit: http://bit.ly/1MHOzqp.
"The overarching life sciences trend of laboratories moving from manual methods to automated workflows continues to drive the use of instruments capable of performing automated NAPI," said Frost & Sullivan Healthcare Senior Industry Analyst Christi Bird. "The mounting installed base of automated NAPI instruments expands sample throughput capabilities and in turn fuels automated kit and reagent sales."
Automated NAPI technology fits in perfectly with laboratories' demand for more accurate data, desire to eliminate costly errors and need to maintain consistent standards across samples. In addition to boosting reliability and reproducibility, as well as reducing the need for multiple runs to verify results, automated sample preparation frees researchers from the lab bench, allowing them to focus on more important tasks. These benefits are now widely accessible to basic research labs due to the launch of affordable benchtop automated NAPI instruments.
However, in the diversified U.S. NAPI automation market, the flexibility of platforms differs greatly between vendors and instruments. Flexibility is ascertained by considering whether a system is closed or open, modules can be added or not, the types of kits available, number and type of samples able to be processed, sample volume equipped for use, and varieties of chemistries capable of being employed, among other factors.
Many NAPI instruments lack the needed combination of flexibility and attributes for some potential end-users. Hesitant to invest in an instrument missing the exact specifications, some end-users stick to manual methods where they can choose various vendors, tweak protocols and move freely between sample types.
"End-user needs vary tremendously within the NAPI market due to the wide range of laboratory budgets and sample throughputs of the customer base," noted Bird. "While some customers view NAPI instruments as luxuries and have not adopted the technology, others treat automation as a necessity."
Given this scenario, some suppliers have begun to compete more aggressively on price to gain market share. Nevertheless, a few sub-segments of the reagents market, particularly plasmid purification, have become commoditized, stalling growth.
US Nucleic Acid Purification and Isolation Markets is part of the Life Sciences (http://ww2.frost.com/research/industry/healthcare/life-sciences) Growth Partnership Service program. Frost & Sullivan's related studies include: US Liquid Handling Markets, Global Next-generation Sequencing Trends, and US Next-generation Sequencing Markets. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
US Nucleic Acid Purification and Isolation Markets
NF16-52
Contact:
Kayla Belcher
Corporate Communications – North America
P: 210.247.2450
F: 210.348.1003
E: kayla.belcher@frost.com
Logo - http://photos.prnasia.com/prnh/20140910/8521405145LOGO
